Retatrutide

Retatrutide engages three structurally related class B G-protein coupled receptors. At the GLP-1 receptor, activation elevates intracellular cyclic AMP in pancreatic beta cells and potentiates glucose-stimulated insulin secretion, while engagement in hypothalamic and brainstem nuclei modulates POMC and AgRP neuronal activity to reduce caloric intake in preclinical feeding studies. At the GIP receptor, signaling contributes additional insulinotropic effects under hyperglycemic conditions and has been implicated in adipose tissue lipid handling.

Activation of the glucagon receptor, predominantly expressed on hepatocytes, increases hepatic cyclic AMP and mobilizes glycogen and lipid stores. In isolation, glucagon agonism elevates glucose output, but when combined with incretin-receptor engagement in a single molecule, investigators have observed that net glycemic effects remain favorable while energy expenditure increases. Preclinical work has reported elevated oxygen consumption and reductions in hepatic triglyceride content in rodent models, consistent with a thermogenic and lipid-mobilizing contribution from the glucagon component. The relative potencies at the three receptors were tuned during medicinal chemistry to balance these opposing actions.

The retatrutide program emerged from Eli Lilly's continued exploration of multi-receptor incretin and glucagon pharmacology following the clinical success of tirzepatide. The molecule was first disclosed in the scientific literature in 2022, when Coskun and colleagues published the preclinical characterization of LY3437943, describing its receptor pharmacology, pharmacokinetics, and effects in rodent and non-human primate models of obesity and diabetes. The disclosure positioned the compound as a deliberate extension of the dual-agonist concept into triple-receptor space.

In 2023, two pivotal phase 2 reports appeared in the New England Journal of Medicine. Jastreboff and colleagues reported the obesity phase 2 results, in which adults with obesity received once-weekly subcutaneous retatrutide across a range of doses over 48 weeks. Mean body-weight reductions reached approximately 24 percent at the highest dose, an effect magnitude that drew substantial attention in the metabolic research community. In a parallel phase 2 report, Rosenstock and colleagues described glycemic and weight outcomes in adults with type 2 diabetes, reporting reductions in glycated hemoglobin and body weight comparable to or exceeding contemporary GLP-1 and dual-agonist benchmarks.

Subsequent disclosures examined the compound in metabolic dysfunction-associated steatohepatitis, with reductions in hepatic fat content reported in imaging substudies, and in cohorts with knee osteoarthritis associated with obesity. The TRIUMPH phase 3 program was initiated to evaluate obesity, type 2 diabetes, cardiovascular outcomes, and sleep apnea endpoints across geographically diverse populations. As of the available scientific record, retatrutide was in active late-stage clinical development without regulatory approval, and longer-term safety and efficacy data continued to accumulate. The compound has also become a frequent reference in academic investigations of how balanced glucagon-receptor agonism modulates energy expenditure when paired with incretin signaling.